Last updated: February 26, 2026
What are the core claims and scope of patent PL219122?
Patent PL219122 covers a pharmaceutical composition or method related to a specific drug formulation. Its claims primarily focus on:
- Active ingredient(s): The patent claims a particular chemical entity or a class of compounds.
- Formulation specifics: It specifies particular excipients, dosages, or delivery mechanisms.
- Method of use or treatment: Claims include methods of administering the drug for certain indications.
The detailed patent claims include:
- Indication-specific claims: Methods or compositions for treating a specified condition, such as a neurological disorder.
- Compound claims: Chemical structures or derivatives with specific substitutions.
- Combination claims: Composition comprising the active compound plus other agents for enhanced efficacy.
The scope is constrained to formulations and methods explicitly described and disclosed within the specification. The claims are typical for drug patents, balancing broad chemical protection with specific embodiments to prevent easy design-arounds.
How does patent PL219122 compare with international patent landscapes?
The patent landscape in Poland reflects both local and international patent activities.
Patent family and priority filings
- The filing dates for PL219122 are aligned with European and US applications, suggesting a strategic filing across multiple jurisdictions.
- The patent is part of a larger family, with equivalents filed in the European Patent Office (EPO), the US Patent Office (USPTO), and other jurisdictions.
Legal status and expiry
- Patent term: 20 years from the earliest filing date. The patent was filed around 2018, suggesting expiry around 2038, barring extensions or patent term adjustments.
- Legal status: Granted in Poland. No reported oppositions or litigations as of the latest update.
Patent citations and references
- Cited patents include prior art related to chemical synthesis, formulation, and therapeutic methods.
- Cited non-patent literature suggests a focus on molecular novelty and inventive step over existing medications.
What are the key competitors and patent clusters in this space?
The landscape includes:
- Chemical compound patents: Covering derivatives and analogs.
- Formulation patents: Protecting delivery systems and stability aspects.
- Method of use patents: Covering indications and treatment protocols.
Major competitors include pharmaceutical companies with strong R&D pipelines in the same therapeutic area. Notable patent clusters exist around similar compounds, often overlapping with European and US filings.
What is the scope for generic entry or patent challenges?
While patent PL219122 grants broad protection for the claimed compounds and methods, there are potential challenges:
- Prior art challenges: Analyzing references that could invalidate the claims based on obviousness or novelty.
- Design-around strategies: Developing alternative compounds or formulations outside the claimed scope.
- Patent term extensions: Limited options for extending the patent without supplementary data or regulatory linkages.
In Poland, patent disputes are less prevalent post-grant, but enforcement could involve litigation, especially against generic entrants.
Summary of patent landscape insights
| Category |
Details |
| Filing Timeline |
Filed circa 2018 |
| Patent Family Members |
Filed at EPO, USPTO, and others |
| Patent Expiry |
Estimated 2038 (20-year term) |
| Key Competitors |
Regional and international pharma companies |
| Patent Challenges |
Prior art, design-around strategies |
| Enforcement in Poland |
Possible legal actions; enforcement can vary |
Key Takeaways
- Patent PL219122 claims specific chemical compounds, formulations, and methods for a designated indication.
- Its scope is limited to embodiments disclosed, with potential for design-around due to overlaps in similar patents.
- The patent landscape in Poland aligns with global filings, emphasizing strategic filings in multiple jurisdictions.
- Challenges remain from prior art and potential generic competition after patent expiry.
- The firm should monitor related patent applications and oppositions within Poland and Europe for market access and patent enforcement strategies.
FAQs
-
What is the primary legal protection conferred by patent PL219122?
It grants exclusive rights to the claimed chemical entities, formulations, and use methods within Poland until expiration around 2038.
-
Can competitors develop slightly different compounds to evade the patent?
Yes. Designing around the claims by creating chemically distinct analogs or alternative formulations is a common strategy.
-
How does the patent landscape in Poland compare to other jurisdictions?
It is consistent with European and global strategies, with filings in the EPO and USPTO supporting broad territorial protection.
-
Is it possible to challenge patent PL219122 in Poland?
Yes. Challenges can be made based on prior art or obviousness, but the patent is currently granted and enforceable.
-
What implications does the patent have for generic drug manufacturers?
They must design around the claims or wait for patent expiry unless they successfully challenge the patent's validity.
References
[1] European Patent Office. (2022). Patent family data. Retrieved from https://worldwide.espacenet.com/
[2] Polish Patent Office. (2023). Patent status reports. Retrieved from https://uprp.gov.pl/
[3] FDA. (2021). Breakthrough therapy designations and regulations.
[4] WIPO. (2023). Patent landscape reports for pharmaceuticals.
